Navigation Links
Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
Date:6/10/2011

BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA).

Pending FDA review and approval, Vertex expects to open the program at clinical sites in the United States as early as July.

"We are delighted that Vertex is making VX-770 available to patients through an expanded access program," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "This underscores Vertex's commitment to do what is right for the CF community."

The company is on track to submit a New Drug Application for VX-770 to the FDA in the second half of 2011.

VX-770 is an oral drug in development that targets the underlying cause of cystic fibrosis.

Results from Phase 3 clinical trials released this year showed that those who took the drug had marked improvements in lung function and other key indicators of the disease, including sweat chloride levels, likelihood of pulmonary exacerbations and body weight.

The CF Foundation worked with Vertex to discover VX-770, and has provided substantial scientific, financial and clinical support throughout the development process.

The Vertex VX-770 drug access program is for people with highly limited lung function and who meet other criteria. For information on eligibility or other details, call Vertex Medical Information at 1-877-634-VRTX (8789).

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting
5. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
6. KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
7. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
8. China Botanic Pharmaceutical Announces Plans to Switch to Renewable Bio-Fuel - Straw Pellets
9. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
10. Qmed Announces Increase in Dedicated Staff as Part of Development Plans for 2011
11. Plans to Overhaul Ambulance Industry Met With Enthusiasm: Online Marketplace for Emergency Medical Services Introduces Largest Selection of Products and Services on the Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016 Progra m m ... of Oxitec , s mosquito in ... by 96 %   Oxitec ... plan to fight wild Aedes aegypti, the dangerous mosquito that spreads ... island of Grand Cayman .  MRCU, a global leader in ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
Breaking Medicine Technology:
(Date:5/5/2016)... Rafael, CA (PRWEB) , ... May 05, 2016 , ... ... of the Year, Derek Pittman, along with his university coaching staff. Together they bring ... girls, with separate sessions run for youth players ages 5-13, and high school players. ...
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
(Date:5/5/2016)... ... , ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as its new ... experience within the healthcare revenue cycle industry. With a primary focus of end-to-end revenue ... Services at Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve the HFMA ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Lung Institute will celebrate its three-year ... seminar at most clinic locations throughout the month of May. To date, the Lung Institute ... rapid growth that we’ve seen is a testament to the success of this treatment and ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central Executive ... Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected as ...
Breaking Medicine News(10 mins):